Abstract
Thirty-one patients affected by advanced ALL entered this study. Twenty (1 in I CR, 9 in II CR, 6 in III CR and 4 extramedullary relapses) were treated with the BMVC conditioning regimen. Eleven (9 in II CR, 2 in III CR) received the Busulfan plus Cytoxan conditioning regimen. Asta-Z 7654-purged marrow was reinfused at day 0. Both protocols were well tolerated. Two patients treated with the BMVC regimen died in aplasia from sepsis; 1 patient died in CR 5 months after transplantation, 13 relapsed after a median time of 4 months (range 1-31). Four patients are in CCR with a median follow-up of 16 months (range 11-24). In the BU + CY treated group no toxic deaths were observed. Four patients relapsed after a median of 3 months (range 2-7) and 7 are in CCR with a median follow-up of 5 months (range 2-28).
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow Transplantation*
-
Busulfan / administration & dosage
-
Carmustine / administration & dosage
-
Carmustine / therapeutic use
-
Child
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / analogs & derivatives
-
Cyclophosphamide / pharmacology
-
Cytarabine / administration & dosage
-
Cytarabine / therapeutic use
-
Drug Resistance
-
Etoposide / administration & dosage
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Male
-
Mitoxantrone / administration & dosage
-
Mitoxantrone / therapeutic use
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery*
-
Preoperative Care / methods*
-
Transplantation, Autologous
Substances
-
Cytarabine
-
Etoposide
-
Cyclophosphamide
-
mafosfamide-lysine
-
Mitoxantrone
-
Busulfan
-
Carmustine